DART Therapeutics Inc., an innovative biotechnology company newest style, which focuses on the development of therapies for Duchenne muscular dystrophy (DMD), and Biovista, a leading provider for the systematic repositioning of drugs, have entered a research cooperation to identify novel candidates for the repositioning of drugs for DMD and develop the technology Biovista "Clinical Outcome Search Space" (COSS) should be used.

Under the agreement, Biovista identify novel candidates for the repositioning of the company and DART Therapeutics will have the option to select a specific number for the further development. Terms of the agreement include an upfront payment and subsequent performance-based payments.

"The repositioning of drugs is an important approach in our overall strategy for the most efficient identification of novel treatments for DMD," said Gene Williams, chief executive officer of DART Therapeutics. "Biovista and the COSS technology are leading the systematic ensure repositioning and us. The widest possible coverage of all the repositioning that can really have a major impact on patients and their families who are waiting for treatment for DMD."

"Is the company DART Therapeutics for a unique model that represents the Entwicklungsarm a large interest group of patients. The company's leadership in DMD is an excellent complement to our own skills in the repositioning of drugs," said Aris Persidis, president of Biovista. "We believe that this kind of cooperation is indicative of interest groups that strive to develop innovative ways to therapies that directly address their specific needs, and we look forward to working with DART Therapeutics."

Biovista is a privately held biotechnology company that specializes in finding new uses for drugs already approved as well as the creation of profiles for their side effects, which are calculated using the corresponding action principle.